French biotech receives Qualified Hit List

24 May 2017

The French biotech company CELLIPSE has taken the next step towards novel treatments for leukaemia patients thanks to the European Lead Factory.

They have now received the so-called Qualified Hit List from the European Lead Factory for their innovative approach targeting the cytoskeleton regulation. Renaud Prudent, Chief Operating Officer of CELLIPSE, thanked the ELF teams involved:  'Despite some unexpected difficulties along the way, they managed to deliver the results that we anticipated. This will allow us to build a second chemistry asset programme, to strengthen our ongoing proprietary lead candidates portfolio of kinase inhibitors for myeloid leukemias.'

Interested? Read more on their website.